TriangleFOR PATIENTS · SOURCE READING
Targeted therapy for BRCA-positive breast cancer
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
NCI patient treatment article for this disease Exact source article; not a clinically reviewed indication or current-standard recommendation.
Context: Targeted Therapy for Breast Cancer
Targeted therapy for BRCA-positive breast cancer
BRCA1 and BRCA2 are genes that produce proteins that help fix damaged DNA. Certain changes, called mutations or pathogenic variants, in these genes can disrupt DNA repair and cause cancer to develop.
The following targeted therapy drugs may be used to treat BRCA1- or BRCA2-positive breast cancer:
olaparib
Source links and citations
talazoparib
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice